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ABSTRACT
Background Mitochondrial disease is often suspected
in cases of severe epileptic encephalopathy especially
when a complex movement disorder, liver involvement
and progressive developmental regression are present.
Although mutations in either mitochondrial DNA or
POLG are often present, other nuclear defects in
mitochondrial DNA replication and protein translation
have been associated with a severe epileptic
encephalopathy.
Methods and results We identiﬁed a proband with
an epileptic encephalopathy, complex movement disorder
and a combined mitochondrial respiratory chain enzyme
deﬁciency. The child presented with neurological
regression, complex movement disorder and intractable
seizures. A combined deﬁciency of mitochondrial
complexes I, III and IV was noted in liver tissue, along
with increased mitochondrial DNA content in skeletal
muscle. Incomplete assembly of complex V, using blue
native polyacrylamide gel electrophoretic analysis and
complex I, using western blotting, suggested a disorder
of mitochondrial transcription or translation. Exome
sequencing identiﬁed compound heterozygous mutations
in CARS2, a mitochondrial aminoacyl-tRNA synthetase.
Both mutations affect highly conserved amino acids
located within the functional ligase domain of the
cysteinyl-tRNA synthase. A speciﬁc decrease in the
amount of charged mt-tRNACys was detected in patient
ﬁbroblasts compared with controls. Retroviral transfection
of the wild-type CARS2 into patient skin ﬁbroblasts led
to the correction of the incomplete assembly of complex
V, providing functional evidence for the role of CARS2
mutations in disease aetiology.
Conclusions Our ﬁndings indicate that mutations in
CARS2 result in a mitochondrial translational defect as
seen in individuals with mitochondrial epileptic
encephalopathy.
INTRODUCTION
Mitochondrial dysfunction is a common cause of
human disease with an incidence of 1:5000 to
1:10 000 live births.1 Despite the high frequency of
disease, a majority of patients remain without a
genetic diagnosis. Mitochondrial disease has been
associated with mutations in 13 mitochondrial-
encoded genes and in >200 nuclear-encoded
genes.2 Furthermore, there are >1000 nuclear
genes that encode mitochondrial-targeted proteins,
providing a large number of probable candidate
genes as the cause of mitochondrial dysfunction.3
The large number of candidate genes and heteroge-
neous manifestations of disease are the main
impediment to the genetic diagnosis. However,
recent developments in high-throughput sequen-
cing have signiﬁcantly increased the detection of
mutations in nuclear-encoded genes associated with
mitochondrial disease.4–6
Despite the increased utility of genetic testing,
providing proof of pathogenicity of novel variants
remains challenging and mitochondrial functional
studies remain an integral part of the evaluation.
The results of functional studies may help narrow
down potential candidate genes to a speciﬁc gene
function as well as provide a means to validate
genetic results. Decreased activity of respiratory
chain enzymes or altered oxidative phosphorylation
coupling can illustrate mitochondrial dysfunction.
Isolated deﬁciency of the activity of a single respira-
tory chain enzyme is typically the result of genetic
alterations in structural subunits or assembly pro-
teins for respiratory chain complexes. Combined
deﬁcient activity of multiple respiratory chain
enzymes may be caused by defects in proteins
required for mitochondrial DNA (mtDNA) main-
tenance, transcription or translation.
Although the clinical ﬁndings in mitochondrial
disease are heterogeneous, central nervous system
involvement is common, often manifesting as neuro-
logical regression or movement disorders. Various
epileptic conditions have been well described in
patients with mitochondrial disease.7–9 Severe mito-
chondrial epileptic encephalopathies are most com-
monly associated with myoclonic epilepsy with
ragged red ﬁbres and Alpers’ syndrome. Patients
with Alpers’ syndrome often present in infancy with
cortical atrophy and prominent epilepsy, which may
evolve into intractable epilepsy,10 11 and a deﬁciency
of respiratory chain enzymes is prominently present
in liver, whereas other tissues, such as skeletal
muscle, can be normal.12 Mutations in the
polymerase-γ gene, POLG, account for the majority
of cases of Alpers’ syndrome.13 14 Other genes
involved in mitochondrial replication and transla-
tion have also been associated with mitochondrial
epileptic encephalopathies.
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We describe a child with a severe epileptic encephalopathy,
complex movement disorder and a combined respiratory chain
enzyme deﬁciency in whom we identiﬁed mutations in a gene
involved in mitochondrial translation. Multiple mitochondrial
respiratory chain enzyme deﬁciencies in liver and decreased syn-
thesis of mtDNA-encoded subunits were consistent with a
defect in either mitochondrial transcription or translation. Using
trio-based exome sequencing, we identiﬁed compound heterozy-
gous mutations in CARS2, a mitochondrial cysteine-speciﬁc
aminoacyl-tRNA synthetase, consistent with the patient’s pheno-
type and the mitochondrial respiratory chain enzyme analysis.
Subject
The infant, the second child of non-consanguineous parents of
Scandinavian ethnicity, presented at 5 weeks of age with epi-
sodes of opisthotonus and feeding difﬁculties resulting in failure
to thrive for which he received a gastrostomy tube and Nissen
fundoplication. His early clinical course was marked for a delay
in acquiring developmental milestones, and he developed hypo-
tonia and abnormal movements. His highest level of develop-
mental function included ambulation with the assistance of a
walker, hitting a toy and babbling. He declined in function over
a 3-year period with regression usually associated with infec-
tions and resulting in the loss of skills such as rolling over,
reaching and grasping. He developed a complex movement dis-
order with chorea, dystonia including oculogyric episodes, myo-
clonus, startle myoclonus and developed microcephaly.
At 3 year 10 months, he developed medically refractory
complex partial status epilepticus, with severe background
slowing, multifocal epileptiform discharges, frequent focal myo-
clonic and complex partial seizures. These seizures were unre-
sponsive to midazolam and pentobarbital infusions, the
ketogenic diet and multiple antiseizure medications. He was dis-
charged in complex partial status epilepticus and has remained
in this condition for >5 years. Myoclonus remained frequent,
but his chorea and dystonia resolved. He had central and
obstructive sleep apnoea and swallowing dysfunction. He devel-
oped osteoporosis and presented spontaneous fractures of both
humeri at age 6 years. Presently, he is alert, has frequent myo-
clonus of his distal limbs or mouth, is severely hypotonic and
does not have antigravity movements of his limbs or head. He is
areﬂexic and has no purposeful or elicited eye movements on
oculocephalic manoeuvre. He communicates with family
members using an augmented communication device by moving
a ﬁnger or foot to activate a button. He receives a very low
caloric diet via G-tube to avoid excessive weight gain.
Brain MRI showed progressive atrophy of the cortex and,
more prominently, of the white matter with focal increased T2
signal in cortex and white matter, a very thin corpus callosum
and atrophic cerebellar vermis (ﬁgure 1). He developed multi-
focal epileptiform discharges on EEG most prominent over the
posterior quadrant, with slowing posteriorly and, at present,
continuous multifocal high-amplitude epileptic discharges on
EEG. Serum lactate was increased in 50% of samples obtained,
up to 5.8 mM maximum. Lactate in spinal ﬂuid was increased at
2.6–3 mM with a normal lactate/pyruvate ratio of 12 and 13,
respectively. Serum alanine was mildly elevated at 511 mM and
cerebrospinal ﬂuid (CSF) alanine was mildly elevated at 45 and
52 mM (normal range 13–48 mM). His albumin has been low
frequently, and almost continually since age 6 years (average of
3.1 g/dL, age-related normal range 3.7–5.6 g/dL). The coenzyme
Q level in serum was normal (0.67 mg/L, normal range
0.4–1.19 mg/L). Other liver function tests such as bilirubin,
transaminases, ammonia and clotting factors have been normal
and renal function has been normal including absence of pro-
teinuria. Biopsies for mitochondrial evaluation in skeletal
muscle, liver and skin were obtained at 3 year 10 months. The
liver showed mild microvesicular steatosis with normal mito-
chondrial ultrastructure, and the skeletal muscle had normal
histology. He had normal enzyme activities for biotinidase and
pyruvate dehydrogenase, and normal molecular investigations
for mitochondrial bioenergetic disorders included mtDNA point
mutations and deletions in leucocytes, complete mtDNA
sequencing in skeletal muscle and sequencing of POLG1, TK2,
ANT1, DGUOK, SUCLA2, POLG2, MPV17, TWINKLE
(C10orf2), RRM2B and TIMM8A. His karyotype was normal,
and array-based comparative genomic hybridisation was negative
for clinically signiﬁcant copy number variations.
METHODS
Respiratory chain enzyme analysis
Respiratory chain enzyme activities for complexes I, II, II+III,
III, IV and citrate synthase (CS) were assayed in post 600 g
supernatants spectrophotometrically on a Cary 300 spectropho-
tometer at 30°C in cultured skin ﬁbroblasts and in skeletal
muscle as described with some modiﬁcations.15 16 For com-
plexes I, II, II+III and CS, enzyme activities were calculated as
initial rates (nmol/min), and for complexes III and IV as ﬁrst-
order rate constants. All activities were normalised to the total
protein content in each sample and expressed as ratios over the
activity of CS and of complex II. The natural log of the activ-
ities and of the ratios in control samples was normally distribu-
ted, and the results were thus expressed as Z-scores. The
Figure 1 Brain MRI. MRI of the brain at age 6 years showing axial and coronal images on a T2-weighted sequence. Global atrophy of the
cerebrum and the cerebellar vermis with secondary ex vacuo dilatation of the lateral and third ventricle is seen. The cerebral white matter shows
atrophy. A red arrow shows a deep sulcus representative of the cerebral atrophy, and the orange arrow illustrates the very thin corpus callosum.
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normal ranges were derived from 25 muscle controls, 16 liver
controls and 20 control ﬁbroblasts.
The integrity of the assembly of complexes I, II, IV and V was
evaluated using blue native polyacrylamide gel electrophoretic
(BN-PAGE) analysis followed by in-gel activity stain in skeletal
muscle and in a cultured skin ﬁbroblast pellet using a previously
published method.17 18 This method can identify defects in
mitochondrial transcription and translation by showing bands of
incompletely assembled complex V as reported earlier.19
DNA extraction
High-quality, unfragmented genomic DNA (A260/A280≥1.8
and A260/A230≥1.9) was extracted from whole blood obtained
from the subject and his parents using a FujiFilm DNA
Extraction Robot, from FujiFilm Medical Systems (Stamford,
Connecticut, USA) using QuickGeneR DNA whole blood kit L,
from Kurabo Industries (Osaka, Japan), and using the salting
out method from QIAGEN following the manufacturer’s
instructions.
Exome sequencing and data analysis
Exome sequencing on the subject and his parents was per-
formed using Nimblegen 44Mb SeqCap EZ Exome V.2.0
(Roche Nimblegen, Madison, Wisconsin, USA) followed by
sequencing on an Illumina HiSeq 2000 (Illumina, San Diego,
California, USA). Approximately 50 million, 90 bp, paired-end
reads were obtained from each individual sequenced. On
average, over 50× coverage was obtained from the subject and
his parents. Sequence reads were analysed using well-established
mapping and variant detection software (details provided in
online supplementary methods). The sequence data from the
patient and parents were used to test for causal variants as previ-
ously described.20
PCR and Sanger sequencing
Variants identiﬁed in CARS2 (NM_024537.2, ENST00000
257347) were further validated by Sanger sequencing in the
subject and his parents. Primers were designed to amplify and
sequence exons 6 and 7 of CARS2 where the identiﬁed sequence
variants are located in the proband. Primers were designed to
amplify and sequence all exon and intron boundaries of CARS2
in the additional 15 subjects. Genomic DNA (100 ng) was amp-
liﬁed using PCR, with reactions and conditions as follows:
Promega GoTaq Hot Start’ kit (Promega, Madison, Wisconsin,
USA) with 1× Master Mix and 400 nM of each primer. The
PCR began with an initial cycle at 95°C for 3 min, followed by
30 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 1 min,
ﬁnishing with extension at 72°C for 5 min. Ampliﬁed PCR pro-
ducts were sequenced using the PCR primers as sequencing
primers on an ABI (Life Technologies, Carsbad, California,
USA) PRISM 3730xl at a commercial Clinical Laboratory
Improvement Amendments (CLIA)-certiﬁed sequencing facility.
Protein analysis
For SDS-PAGE, 5 mg of protein was separated on a 5–20% gra-
dient polyacrylamide gel with sodium dodecyl sulfate followed
by western blotting, and detection using the appropriate
primary antibody, followed by incubation with horseradish per-
oxidase (HRP)-conjugated secondary antibody, and visualised by
chemiluminescence. Assembly of mitochondrial complexes was
further evaluated by western blotting after BN-PAGE of 10 mg
of mitochondrial protein, and probed with an antibody against
the complex I subunit NDUFS2 (Mitosciences, MS114), a
subunit that incorporates into the early stages of complex I
assembly. The full-length amino acid sequences of human
CARS2 and the Escherichia coli cysteinyl-tRNA syntethase-
tRNACys complex were aligned and the relative positions of
homologous residues were modelled using the crystal structure
of the E. coli enzyme (1U0B).21
Aminoacylation assay
Aminoacylation of mt-tRNA-Cys was analysed as described pre-
viously.22 Brieﬂy, total RNA was extracted from ﬁbroblasts using
Trizol reagent (Life Technologies) following the manufacturer’s
instructions, with the ﬁnal pellet resuspended in 10 mM NaOAc
at pH 5.0 and kept at 4°C to preserve the aminoacylation state.
For the deacylated control, the pellet was resuspended in
200 mM Tris-HCl at pH 9.5 and incubated at 75°C for 5 min,
followed by RNA precipitation and resuspension in 10 mM
NaOAc at pH 5. Next, 15 mg of RNA was separated on a 6.5%
polyacrylamide gel (19:1 acrylamide:bisacrylamide) containing
8 M urea in 0.1 M NaOAc pH 5.0 at 4°C and electroblotted
(Bio-Rad, Trans-Blot Cell) onto a nylon transfer membrane
(Hybond, GE). Following UV-crosslinking, the membrane was
hybridised with appropriate radiolabelled riboprobes, washed
and imaged using a PhosphorImager.
Correction studies
The full-length CARS2 cDNA in vector pOTB7 was obtained
from Open Biosystems (Catalog MHS1011-60885 Accession
(genbank): BC007220). The cDNA fragment was excised using
EcoRI and XhoI and subcloned into the pCHAC-MCS-
IRES-mWasabi vector of the Gryphon retrovirus expression
system, which contains the 50LTR, the packaging signal and the
30LTR with the gene inserted in the multicloning site followed
by an IRES and a mWasabiGFP protein (Allele Biotechnology,
San Diego, California, USA). The vector was transfected into
the Gryphon amphotrophic packaging cells by electroporation
using the Amaxa Nucleofector II electroporation system (Lonza
Group, Basel, Switzerland). The resulting viral supernatant used
for transduction of the patient cultured skin ﬁbroblasts con-
tained 4 mg/mL polybrene. More than 75% of ﬁbroblasts
showed active ﬂuorescence from the WasabiGFP showing good
transfection efﬁciency. The effect of the introduction of the
native CARS2 cDNA construct was followed by BN-PAGE gel
analysis.
Additional patient samples
To identify the frequency of CARS2 mutations in patients with
mitochondrial translation defects, samples from 15 other
patients were identiﬁed. These patients each had a combined
respiratory chain enzyme deﬁciency, fragmented complex V on
BN-PAGE analysis and normal mtDNA analysis, thus indicating
a defect in either mitochondrial transcription or translation.19
Primers were designed to amplify and sequence all exons and
exon–intron boundaries of CARS2 and subjects were Sanger
sequenced after PCR ampliﬁcation.
RESULTS
Respiratory chain enzyme analysis
We observed a combined deﬁciency of the activities of complex
I and III and low activity of complex IV (not statistically signiﬁ-
cant) in the liver of the subject (see online supplementary table
S1). In muscle, there was a tendency towards low activity for
complexes I and IV, which did not reach statistical signiﬁcance.
This may be due to a compensatory ampliﬁcation of mtDNA as
a result of mitochondrial dysfunction. This is supported by the
signiﬁcant elevation of mtDNA copy number in muscle at 315%
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of age and tissue-matched controls (value: 5506; control: 1746
±361). In ﬁbroblasts, complex IV activity tended to be low as
well. The BN-PAGE gel analysis with in-gel activity staining
showed the presence of additional bands reﬂecting incomplete
assembly of complex V present in both skeletal muscle and
cultured skin ﬁbroblasts (ﬁgure 2A, B). Such bands of lower
molecular mass in complex V have been shown to occur in
patients with defects in complex V assembly, with mtDNA
depletion, or in defects in mitochondrial transcription or trans-
lation.19 The combined deﬁciency in liver indicates that the deﬁ-
ciency is not limited to complex V assembly, and a western blot
with an antibody against NDUFS2 indicated incomplete assem-
bly of complex I (see online supplementary ﬁgure S1). The high
mtDNA copy number in skeletal muscle excludes mtDNA
depletion syndrome, thus indicating that the defect affects
mitochondrial transcription, RNA processing or translation.
A large number of genes are involved in mitochondrial RNA
transcription and processing and in the mitochondrial
translation process, thus making an exome analysis approach
preferable.23–29
Exome sequencing
Exome sequencing was performed in the proband and the
unaffected parents. The downstream analysis was focused on
non-synonymous coding variants, coding InDels and variants
affecting splice sites. We ﬁrst ﬁltered out common variants
present in dbSNP and 1000 Genomes data. Parental exome
sequencing data were used to identify possible pathogenic
variants under various inheritance models including dominant
(de novo mutations) and recessive (compound heterozygous,
homozygous and X-linked hemizygous mutations) models. This
resulted in the identiﬁcation of three candidate genes, DMXL1,
CCDC120 and CARS2, which were considered for further ana-
lysis (see online supplementary table S2).
Using a recessive inheritance model, we identiﬁed two hetero-
zygous, non-synonymous sequence variants in the mitochondrial
cysteinyl-tRNA synthetase, CARS2, that were considered poten-
tially pathogenic. The patient inherited an in-frame deletion
c.649_651delGAG (p.Glu217del) from his father and a mis-
sense mutation c.752C>T (p.Pro251Leu) from his mother in
CARS2. Sanger sequencing conﬁrmed the presence of both the
mutations in the patient and inheritance of one mutation from
each parent, respectively. Both mutations affect highly conserved
residues (ﬁgure 3) in the cysteinyl-tRNA synthetase located
within the conserved functional ligase domain (Cys-tRNA/
MSH-ligase). The missense mutation Pro251Leu is predicted
deleterious by bioinformatics software (Polyphen2, score 1.0).
The Pro251 missense mutation was modelled on a homologous
structure from E. coli (1U0B). The deleted amino acid Glu297
could not be modelled because it is located in a nine amino acid
region that has no homology in the bacterial enzyme. Pro251 is
located in the CP domain near several important residues
including His254, which is involved in hydrogen bonding with
RNA phosphates; Trp253, which is involved in tRNACys sub-
strate binding; and a conserved group of four hydrophobic
amino acids (Ile169, Trp242, Thr166, Val121) neighbouring
Pro251 in the 3D structure.21 This suggests that the mutation
causes a structural change in an important region of CARS2 (see
online supplementary results, ﬁgure S2 and S3).
CARS2 (NM_024537.2) contains 15 exons (transcript length
1.88 kb) encoding a mitochondrial-targeted (62 AA mitochondria-
targeting peptide) protein with 564 amino acid residues
(NP_078813.1; CCDS9514.1). At the time of analysis, defects in
CARS2 had not been reported or associated with a speciﬁc pheno-
type. However, this ﬁnding was consistent with the pathophysi-
ology of other reported aminoacyl-tRNA synthetase (ARS)
defects, where mutations are mostly clustered in conserved regions
of the core catalytic domain and the tRNA anticodon-binding
domain.30 Thus, CARS2 was considered the best candidate for a
role in disease aetiology prompting further investigation.
Mitochondrial tRNA aminoacylation analysis
Functional impact of the CARS2 mutations on the mitochondrial
cysteinyl-tRNA was assessed by high-resolution northern blot-
ting of RNA isolated from patient primary skin ﬁbroblasts. The
use of low pH throughout the procedure allows for distinction
Figure 2 Characterisation of biochemical and molecular defects in subject cells and correction studies. Blue native polyacrylamide gel analysis of
mitochondrial respiratory chain complexes I–V with in-gel activity staining, assayed in skeletal muscle (A) and cultured skin ﬁbroblasts (B) from the
proband compared with a healthy control. In both tissues from the proband, bands with a lower molecular mass were seen following staining for
complex V indicating the presence of incompletely assembled complex V. (C) Correction studies by transfection of wild-type CARS2 into
patient-cultured skin ﬁbroblasts. Before transfection, an additional lower band and a faint middle band are seen, representing incomplete assembly
of complex V. After transfection of the cultured skin ﬁbroblasts with the wild-type CARS2 cDNA, these additional bands representing incompletely
assembled complex V were no longer present.
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between the aminoacyl-tRNA and the uncharged tRNA.
A decrease of the ratio between the aminoacylated and deacy-
lated form of mt-tRNACys was detected, whereas the aminoacy-
lation of control mt-tRNAs, tRNAHis and tRNALeuUUR was
normal (ﬁgure 4). Additionally, the steady-state levels of ami-
noacylated tRNACys were normal in the patient-derived sample
compared with the controls (ﬁgure 4).
Protein analysis and correction studies
Western blot analysis was performed in cultured skin ﬁbroblasts
to analyse the effect of the CARS2 mutations on CARS2 protein
levels. CARS2 was signiﬁcantly reduced in the patient compared
with controls (see online supplementary ﬁgure S4). To further
conﬁrm the role of CARS2 in the observed phenotype, we
carried out retroviral transfection of normal CARS2 into the cul-
tured skin ﬁbroblasts from the patient. The full-length, wild-
type CARS2 cDNA in a retroviral expression construct was
introduced with high transfection efﬁciency (75%, see
’Methods’). The additional bands resulting from incomplete
assembly of complex V in patient’s cultured skin ﬁbroblasts on
BN-PAGE were no longer visible after normal CARS2 cDNA
transfection (ﬁgure 2C). This result indicated correction of the
biochemical phenotype by the transfection with normal CARS2.
CARS2 mutation screening
Fifteen additional subjects with biochemical evidence of defects
in mitochondrial transcription or translational were evaluated
for CARS2 mutations. Sanger sequencing of all 15 coding exons
and exon–intron boundaries of CARS2 did not identify potential
pathogenic mutations. In order to potentially identify other sub-
jects with a deﬁciency of CARS2, eight international mitochon-
drial and exome sequencing centres were contacted to evaluate
Figure 3 Pathogenic variants in CARS2. (A) Partial chromatograms showing Sanger sequencing results of CARS2 in the patient and his parents.
The patient has an in-frame deletion (c.649_651delGAG, p.Glu217del) inherited from his father and a missense mutation (c.752C>T, p.Pro251Leu)
inherited from his mother. (B) Comparative analysis of CARS2 proteins from multiple species demonstrated that Glu217 and Pro251 (highlighted in
red) are evolutionarily conserved. Orthologs were identiﬁed by using BLASTP, and the alignments were performed by using ClustalW. Protein
accession numbers are in parentheses. (C) Top panel shows the 15 exons of CARS2 cDNA as grey boxes. Bottom panel shows the CARS2 protein
domains, including mitochondrial targeting sequence (MTS), the catalytic cysteine-tRNA ligase domain and the anticodon binding domain. Locations
of variants are indicated by arrows. Paternal in-frame deletion is located in exon 6 and maternal missense mutation is located in exon 7. Both
variants are located within the ligase domain of CARS2 protein. WT, wild-type.
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existing exome sequencing data. No other subjects with poten-
tial CARS2 mutations were identiﬁed.
DISCUSSION
Disorders of mitochondrial translation are an increasingly recog-
nised cause of combined respiratory chain enzyme deﬁciency.25
Mitochondria possess their own translation machinery, which
includes ribosomal and tRNAs encoded by mtDNA. In addition,
mitochondrial translation requires nuclear encoded proteins
including post-transcriptional tRNA modiﬁers, ARSs, mitochon-
drial ribosomal proteins, translation initiation factors, elong-
ation factors and peptide release factors.25 To date, defects in
36 nuclear-encoded mitochondrial translation genes have been
implicated in human disease (table 1).
ARSs are key enzymes in the translation of mRNA into pro-
teins since they catalyse the speciﬁc attachment of each of the
20 amino acids to the corresponding tRNA. ARSs are ubiqui-
tously expressed enzymes that are present in most species
ranging from bacteria to humans. Because protein translation
also occurs in the mitochondria, ARSs activity is required in
these organelles.31 To facilitate their import, nuclear-encoded
ARSs carry a mitochondrial targeting sequence within the mito-
chondrial ARSs (mt-ARSs) polypeptide. In total, 17 of the 37
nuclear-encoded ARSs genes including CARS2 are exclusively
mitochondrial targeted, two are bi-functional in cytoplasm and
mitochondria, whereas one of the mt-tRNA (Gln) is aminoacy-
lated via an indirect pathway.32 Thus, the mutations in CARS2
detected in our patient, both of which are predicted to be dele-
terious, are likely to lead to defects in mitochondrial translation.
Leukodystrophy is a common ﬁnding in mt-ARSs deﬁciency,
but the clinical spectrum also includes cardiomyopathy (AARS2),
myopathy-lactic acidosis-sideroblastic anaemia (YARS2) and pon-
tocerebellar hypoplasia (RARS2).33 34 The clinical phenotype in
our patient was consistent with a severe mitochondrial epileptic
encephalopathy with a complex movement disorder including
severe oculogyric dystonia and mycolonus. Mild liver dysfunc-
tion with low albumin and steatosis has been noted in patients
with POLG mutations. Defects in another mt-ARSs, FARS2,
have also been associated with a very similar phenotype, which
included fatal mitochondrial infantile-onset Alpers-like enceph-
alopathy,35 36 and epileptic encephalopathy was also noted in a
patient with mutations in VARS2.37 Recently, two siblings with
severe myoclonic epilepsy and progressive cognitive decline
were described with homozygous mutations in CARS2.38 These
siblings presented at 9 and 5 years, respectively, and were
reported to make academic progress prior to onset of symp-
toms. Our patient presented in the neonatal period, and the
clinical course was marked by a complex movement disorder
not described in the previous report. All of the patients thus far
described have a complex and progressive epileptic disorder
with global brain atrophy noted on MRI. The similarity
between the phenotypes of the two siblings and our patient
lends further support to the causality of the CARS2 mutations
detected in our patient.
Figure 4 Mitochondrial tRNA
aminoacylation analysis by northern
blotting. Northern blot analysis of
mitochondrial tRNA aminoacylation in
total RNA samples from the patient
and control ﬁbroblasts (control
1–control 3). Membranes were
hybridised with radioactive tRNA
probes as indicated. ‘dAc’ indicates
deacylated control sample.
Densitometric quantiﬁcation of the
northern blots is shown on the right of
each blot.
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In several mt-ARSs defects, a very limited phenotype has been
observed in the skin ﬁbroblasts from patients, including normal
respiratory chain enzyme activities, normal BN-PAGE gel ana-
lysis and normal mitochondrial translation assays.37 39 40
However, the identiﬁcation of a functional defect using
BN-PAGE in the proband’s cultured skin ﬁbroblasts provided us
a means to evaluate the causality of a novel gene through cor-
rection of the functional defect by transfection with the native
gene and mitochondrial tRNA aminoacylation analysis by north-
ern blotting. Furthermore, a mouse strain carrying homozygous
missense mutations in Cars2 appears to have neurological phe-
notypes including tremors, induced hyperactivity and head
bobbing.41 42 These neurological phenotypes in the mouse
appear to be age-related and correlate well with the complex
movement disorders and regression observed in our patient.
The analysis of such model organisms at the organismal, tissue
and cellular levels will lead to a better understanding of the role
of CARS2 in the aetiology of the disease phenotype observed in
our patient.
The identiﬁcation of the genetic cause of severe mitochon-
drial infantile epileptic syndromes is difﬁcult when mutations in
POLG and C10orf2 (TWINKLE) have been excluded. Often,
the biochemical abnormalities are only present in liver despite
minimal symptoms of liver dysfunction such as low albumin
levels. Therefore, in patients with neurodegenerative disease,
enzyme studies should include liver as well as skeletal
muscle.43 44 Defects in mitochondrial translation, particularly
FARS2, VARS2 and CARS2, expand the known causes of this
devastating condition.
In summary, we have identiﬁed compound heterozygous
mutations in CARS2 in a patient with a combined respiratory
chain enzyme deﬁciency using exome sequencing, followed by
relevant functional studies to support the genetic ﬁnding. This
report suggests that mutations in CARS2 are an important cause
of a mitochondrial epileptic syndrome and highlights the
important contribution of high-throughput sequencing in the
genetic diagnosis of suspected mitochondrial disorders.
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Table 1 Nuclear-encoded genes associated with defects in mitochondrial translation
Gene OMIM Function Clinical symptoms
AARS2 612035 Aminoacyl-tRNA synthetase Cardiomyopathy
CARS2 612800 Aminoacyl-tRNA synthetase Mitochondrial encephalopathy
DARS2 610956 Aminoacyl-tRNA synthetase Leukoencephalopathy
EARS2 612799 Aminoacyl-tRNA synthetase Leukoencephalopathy
FARS2 611592 Aminoacyl-tRNA synthetase Mitochondrial encephalopathy
HARS2 600783 Aminoacyl-tRNA synthetase Ovarian dysgenesis, sensorineural hearing loss
IARS2 612801 Aminoacyl-tRNA synthetase Cataracts, sensorineural hearing loss, encephaloneuromyopathy
LARS2 604544 Aminoacyl-tRNA synthetase Ovarian dysgenesis, sensorineural hearing loss
MARS2 609728 Aminoacyl-tRNA synthetase Ataxia
NARS2 612803 Aminoacyl-tRNA synthetase Myopathy, encephalopathy
RARS2 611524 Aminoacyl-tRNA synthetase Pontocerebellar hypoplasia
SARS2 612804 Aminoacyl-tRNA synthetase Hyperuricemia, pulmonary hypertension, renal failure, alkalosis
TARS2 612805 Aminoacyl-tRNA synthetase Mitochondrial encephalopathy
VARS2 612902 Aminoacyl-tRNA synthetase Mitochondrial encephalopathy
YARS2 610957 Aminoacyl-tRNA synthetase Myopathy, lactic acidosis, sideroblastic anaemia
GFM1 606639 Elongation factor Hepatoencephalopathy
TSFM 604723 Elongation factor Encephalopathy, cardiomyopathy
TUFM 602389 Elongation factor Mitochondrial encephalopathy
MTFMT 611766 Initiation and elongation factor Leigh syndrome
MRPL3 607118 Mitochondrial ribosomal protein Cardiomyopathy
MRPL44 611849 Mitochondrial ribosomal protein Cardiomyopathy
MRPS16 609204 Mitochondrial ribosomal protein Agenesis corpus callosum, lactic acidosis
MRPS22 605810 Mitochondrial ribosomal protein Hypotonia, cardiomyopathy, tubulopathy
C12orf65 613541 Peptide release factor Encephalomyopathy
MTPAP 613669 Polyadenylation of mRNA Spastic ataxia
LRPPRC 607544 Post-transcriptional regulation Leigh syndrome
GTPBP3 608536 Post-transcriptional tRNA modification Cardiomyopathy, mitochondrial encephalopathy
MTO1 614667 Post-transcriptional tRNA modification Cardiomyopathy
PUS1 608109 Post-transcriptional tRNA modification Myopathy, lactic acidosis, sideroblastic anaemia
TRIT1 Post-transcriptional tRNA modification Mitochondrial encephalopathy
TRMU 610230 Post-transcriptional tRNA modification Liver failure, deafness
ELAC2 605367 Post-transcriptional tRNA processing Cardiomyopathy
HSD17B10 300256 Post-transcriptional tRNA processing Cardiomyopathy, mitochondrial encephalopathy
PNPT1 610316 RNA turnover (or RNA import) Encephalomyopathy, deafness
TACO1 612958 Translation activation Leigh syndrome
RMND1 614917 Unknown Encephaloneuromyopathy
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